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Systemic Sclerosis is a devastating vascular, connective and a multisystem 
autoimmune disease characterized by fibrosis of skin and internal organs, 
exhibiting various forms of disease conditions. Pulmonary arterial 
hypertension (PAH) is one of the clinical manifestations that arise as a result 
of cellular and molecular vascular damage in the vascular wall, and is one of 
the leading causes of death in systemic sclerosis (SSc). SSc-PAH is a 
progressive depleting condition that can lead to right-sided heart failure and 
death. Oxidative stress is largely evidenced in the development of arterial 
hypertension in SSc. This may give rise to unbalanced redox homeostasis that 
could further bring about vascular remodeling characterized by Vascular 
Smooth Muscle Cells (VSMC) hypertrophy and hyperplasia and ECM 
deposition leading to subsequent obliterative vasculopathy and vessel 
occlusion. So it is likely that circulating pro-oxidant factors may be involved in 
the pathogenesis of SSc-PAH by inducing VSMCs activation and phenotypic 
switch.  So we speculate, that in SSc patients associated with Pulmonary 
Arterial Hypertension (PAH), circulating factors may drive an aberrant 
vascular remodeling by exerting pro-oxidant and pro-fibrotic effects on 
Human Pulmonary Arterial Smooth Muscle Cells (HPASMCs) and activate 
collagen I synthesis. To test this hypothesis, we exposed primary Human 
Pulmonary Artery Smooth Muscle Cells (HPASMCs) to serum obtained from 
SSc patients with or without PAH and healthy donors (HD) and looked for the 
production of reactive oxygen species (ROS) and collagen I synthesis. From 
our study, we found that SSc-PAH patients’ circulating factors exhibited pro-
oxidant effect by inducing ROS generation through NOX2 in HPASMCs and we 
also found that, circulating factors exhibited pro-fibrotic effect by inducing 
activation of collagen I synthesis in HPASMCs via ERK signaling, thus asserting 
the vascular damage in SSc patients. 
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Limited cutaneous SSc (lcSSc) 
Diffuse cutaneous SSc (dcSSc) 
Vascular smooth-muscle cells (VSMCs) 
Pulmonary Arterial Hypertension (PAH) 
Vascular remodeling (VR) 
Oxidative Stress (OS) 
Reactive Oxygen Species (ROS) 
Nicotinamide Adenine Dinucleotide Phosphate-Oxidase (NADPH Oxidase or 
NOX) 
Human Pulmonary Artery Smooth Muscle Cells (HPASMCs) 
Pulmonary Artery (PA) 
Endothelin (ET) 
Extracellular signal-regulated kinase (ERK) 
Right heart catheterization (RHC) 
Healthy donors (HD) 
Right ventricular systolic pressure (RVSP) 
Dichlorodihydrofluorescein-diacetate (H2-DCFDA) 
Collagen type-I(COL1A1) 
Lentiviral vector (LV), Forced vital capacity (FVC) 
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CHAPTER 1. INTRODUCTION 
1.1 Historical Background  and  Definition of Systemic Sclerosis 
Systemic Sclerosis (SSc) is also called as Scleroderma or Systemic 
Scleroderma or Familial Progressive Scleroderma or Progressive Scleroderma. 
The first recitation of skin diseases consubstantial to SSc were reported as 
early as Hippocrates (460 - 370 B.C.), that are cited by the detailed historical 
account of SSc by Rodnan and Benedek in 1962 [1, 2]. However, Italian 
physician and dermatologist Carlo Curzio in 1753 [3] was the first to describe 
this disease condition. He reported about a 17-year old woman who had 
excessive tension and hardness of skin and she could hardly move her limbs. 
Goetz gave the name progressive systemic sclerosis or systemic sclerosis in 
1945 [4], and this has become widely accepted term for this disease. 
Scleroderma was recognized as a clinical entity in mid-19th century with its 
present name [5]. 
More than 20 descriptive names had been proposed in the 19th century 
before this disease condition was named as sclerodermie or scleroderma. 
Systemic Sclerosis is derived from the Greek words ‘scleros’ and ‘derma’, 
means thickened, hardened skin. It is integrated by two words Systemic and 
Sclerosis where in Systemic refers to affecting a particular body system, or 
circulating through the entire body and Sclerosis refers to abnormal 
thickening or hardening of a body part. It is a connective tissue and a chronic 
multisystem autoimmune disease characterized by vasculopathy, diffuse 
fibrosis of skin and various internal organs. Systemic sclerosis involves 
hardening of internal organs and stops them working normally. It is a rare, 
heterogeneous and a slow-motion disease, but can be very serious. It varies 
greatly from person to person and hence there are many symptoms and 
problems that may progress or evolve with systemic sclerosis. As of now, 
there is no cure for scleroderma but effective treatments for some phenotypes 
of the disease are available. 
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1.2 Classification of SSc 
 
There are mainly two classes of SSc, named as Localized & Systemic 
Scleroderma.  Localized scleroderma does not involve internal organs. But 
systemic scleroderma has been given more importance due to its involvement 
of internal organs. It has two subsets based on the extent of skin involvement 
(as shown in Fig. C) , namely Limited cutaneous SSc (lcSSc) with skin 
involvement distal to the elbows and knees, with or without involvement of 
face and Diffuse cutaneous SSc (dcSSc) with skin involvement of the 
proximal limbs and/or trunk [6, 7]. The distinguishing features between the 
both the subsets are explained in the table below [8]. 
Figure C: Skin involvement in LSSc & DSSc 
                                                                                        .                                         Table 1.Distinguishing Fetures:LSSc & DSSc  
Baltimore 2002; Ferri C. et al (Medicine) 81(2):139-153.                       Dinesh Khanna. Indian Journal of Rheumatology June 2010                                                 
  
 
1.3 Pulmonary Hypertension 
There are several heterogeneous clinical manifestations of SSc involving 
cutaneous, vascular, pulmonary, gastrointestinal, endocrine, neurologic, 
cardiac, renal and muscoskeletal. Pulmonary hypertension is one of the 
serious manifestations that develop in SSc patients. Actually, pulmonary 
hypertension is an abnormal increase of the pressure in the blood vessels of  
6 
Dr. Tulasigeri  M.Totiger 
“Cellular and Molecular Study of Vascular Damage during Systemic Sclerosis” 
PhD Thesis in Biochemistry, Physiology and Molecular Biology of PhD School in 
Biomolecular and Biotechnological Sciences, University of Sassari 
 
 
                                                                                                                                      
                                                                                                                                                         Introduction 
the lungs. This is usually called as the “high blood pressure” of the lungs. In 
normal functioning of lungs, the pressure in the blood vessels is about one-
quarter of the pressure in the arteries of the body and this can temporarily 
adapt to increased pressures that occur during exercise [9]. But during                                                                                                                                  
pulmonary hypertension, in the lungs, small arteries are very much narrow, 
that’s why the pressure rises in these vessels. Because of this, the right side of 
the heart, which pumps blood into the lungs, will have to pump against a 
higher resistance of blood flow. This would cause more difficult to pump the 
blood through the lungs, exactly when increased flow is needed, in a patient 
when exercises [9].Pulmonary arterial hypertension (PAH) is described as a 
progressive condition characterized by elevated pulmonary arterial pressures 
causing right ventricular (RV) failure [10]. In medical terms it is defined as an 
increase in mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg at rest as 
assessed by right heart catheterization [11,12]. Different hemodynamic 
definitions of PH are described based on pulmonary capillary wedge pressure, 
pulmonary vascular resistance (PVR) and cardiac output (CO).Clinical groups 
1, 3, and 4 are of  pre-capillary PH,  group 2 compose  post-capillary PH [13-
19] and group 5 linked to PH with unclear or multifactorial etiologies.  
 
1.4 Classification of Pulmonary Arterial Hypertension (PAH) 
The revised classification comprises of 5 different types of PAH, with the 
inclusion of subclasses & their subtypes [13, 16-19]. They are as follows. 
1. Pulmonary arterial hypertension   
2. Pulmonary hypertension due to left heart disease 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
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4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
PAH or Group 1 PH include PAH having different etiologies. The pathological 
characteristics of this group involve pulmonary arterial endothelial cell (EC) 
dysfunction, pulmonary artery EC and smooth muscle cell (SMC) proliferation,                                                                                                                                       
vasoconstriction and in situ thrombosis [20]. The sub-groups of PAH include 
common clinical characteristics and share similarities in terms of 
management [17]. PAH remains an incurable disease process, even though                                                                                                                                        
there are many new available therapies from the last two decades. If PAH not 
interrupted, would leads to right heart failure and death [22, 23, 24]. 
1.5 Systemic Sclerosis-associated Pulmonary Arterial 
Hypertension (SSc -PAH) 
The existence of a small vessel vasculopathy is one of the distinguishing 
features of SSc & hence SSc patients are at greater risk of developing & 
arriving at disease condition called PAH.  This disorder is now admitted as the 
major cause of morbidity and mortality. So the newest (2013) American 
College of Rheumatology / European League Against Rheumatism 
(ACR/EULAR) classification criteria has given importance & recognition to it  
and provided equal weight and consideration to SSc-PAH as similar to other 
manifestations of SSc. PAH is a life-threatening ailment, which could rapidly 
progress to severe right heart failure [13, 14]. The prevalence of PH in 
connective tissue diseases is usually estimated on the basis of 
echocardiographic examinations, however most of the recent studies show 
that for systemic sclerosis (SSc), PH assessment depends on the basis of strict 
hemodynamic criteria [25,26,27]. Pulmonary arterial hypertension (PAH) is 
described as a progressive pulmonary vascular disease that involves  
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narrowing or tightening or constriction of the pulmonary arteries that 
connect the right side of the heart to the lungs. PAH is characterized by an 
increase in mean pulmonary arterial pressure (PAP) to ≥25 mmHg at rest, and 
a mean primary capillary wedge pressure of ≤15 mmHg [15]. As PAH 
progresses, the blood flow through the pulmonary arteries is restricted and 
because of this, there occurs an enhanced strain of pumping blood through the 
lungs, resulting in the enlargement of the right side of the heart. As a result of 
this strain on the heart and also due to the reduction in blood to the left heart 
and also to the systemic circulation through the lungs lead to usual symptoms 
of PAH, such as Dyspnea (breathlessness), fatigue, weakness, Exertional syncope, 
angina, and abdominal distension [12].The parameter that indicates a high risk 
of future development of PAH in patients with SSc is the existence of 
‘borderline’ pressures aligning between 21 and 24mmHg [28, 29]. 
                                                                                                                                      
1.6 Epidemiology of SSc-PAH 
PAH is caused by the pulmonary vascular remodeling and can either occur 
alone (SSc-PAH), or may advance secondary to pulmonary parenchymal 
involvement resulting as interstitial lung diseases (ILD-PH). ILD-PAH is the 
most frequent and a serious complication of SSc. It occurs in 75% of cases and 
is more frequent in diffuse cutaneous SSc (DcSSc) [30-33]. Based on right 
heart catheterization (RHC), the prevalence of PAH other than ILD-PH is 
between 7.85 and 12% [30, 31] and more common in later stage of limited 
cutaneous SSc (LcSSc). Isolated PAH (SSc-PAH) is more common in LcSSc, 
when compared to DcSSc, however few recent studies [30-38] suggest that the 
prevalence of PAH is similar in both limited and diffuse cutaneous SSc 
patients. SSc-PAH has worse prognosis than that of IPAH [39] and patients are 
at higher risk of death than IPAH patients. Even though both types share  
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similar histopathological & haemodynamic characteristics but estimated one-
year survival rates are 55% and 84%, respectively [40]. PAH among patients 
with SSc is estimated to be 0.61 cases per 100 patient-years [41]. Median 
survival time of SSc patients with PAH is between 1 to 3 years [40, 42] and SSc 
patients with ILD alone have a median survival of 5–8 years [43]. 
 
1.7 Subtypes of PAH in SSc  
Pulmonary hypertension, defined by mean pulmonary arterial pressure 
greater than 25 mm Hg, can be isolated in SSc, occurring as PAH (SSc-
associated PAH or SSc-PAH), and this one is due to pulmonary vascular                                                                                                                                                                                                                                          
remodeling. The other subtype is in combination with ILD [pulmonary 
hypertension (PH)-ILD] or (ILD-PH) [44,45], which may develop secondary 
due to parenchymal involvement.  
A. Isolated Pulmonary Arterial Hypertension {IPAH} (in the 
absence of significant pulmonary fibrosis or Interstitial Lung 
Disease) 
PAH in SSc patients without pulmonary fibrosis or ILD is a severe 
complication due to narrowing or occlusion of small pulmonary arteries 
caused by smooth muscle hypertrophy, intimal hyperplasia, inflammation, 
thrombosis in situ. The breathlessness (dyspnea) progression rate from 
normal exercise tolerance to oxygen dependency is about 6–12 months & the 
mean duration of survival is 2 years. Unlikely, SSc patients with PAH with 
respect to interstitial lung disease have a same degree of disability, but the 
difference is that they progress more slowly for a period more than 2, up to 10 
years [46-50]. The prevalence of Isolated PAH in SSc (without significant  
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pulmonary fibrosis) is between 7 and 12% of patients [11]. However, the most 
frequent type of pulmonary hypertension in SSc patients is Group I PAH [51]. 
B. PAH associated with pulmonary fibrosis  
With either of both the (diffuse or limited) forms of the disease, more than one 
third of SSc patients have pulmonary fibrosis. The clinical tests have revealed 
alveolar, interstitial, peribronchial and pleural fibrosis. This kind of PAH has 
relatively slow progression & has gradual elevation in the resistance of 
pulmonary vasculature resulting in the widespread pulmonary fibrosis [47].  
ILD is prevalent in up to 75% of SSc cases and is more frequent in diffuse 
cutaneous SSc (DcSSc), being often complicated with pulmonary hypertension, 
plays significant role in PAH development [45].  
                                                                                                                                       
1.8 Introduction and Biochemistry of Oxidative Stress (OS). 
From long time it has been known that Oxidative stress plays a major role in 
the pathogenesis and vascular damage of SSc-PAH, which is elucidated by the 
abnormal redox state in SSc patients [52]. It is well documented that ROS 
mediates vascular damage in the vascular wall [53]. “Any species which is 
capable of independent existence and contains one or more unpaired electron 
in atomic or molecular orbitals” are termed as free radicals [54] and also 
called by the name Reactive Oxygen Species (ROS). Since free radicals possess 
atomic structure that has an unpaired electron in the outer orbital, gives them 
a special configuration of great instability. This provides it very un-stable 
state, making it short-lived and extremely reactive, with a tremendous 
capacity to interact nonspecifically with the diverse set of molecules of the cell 
structure such as carbohydrates, lipids, proteins and nucleic acids [55].Pro-
oxidant denotes to any endobiotic or xenobiotic that induces oxidative stress  
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either by generation of ROS or by inhibiting antioxidant systems. It can 
include all reactive, free radical containing molecules in cells or tissues [56]. 
Pro-oxidants may be broadly classified into two categories as Exogenous and 
Endogenous. Exogenous pro-oxidants include pro-oxidants derived from 
dietary ingredients, toxicants, drugs, pathogens, environmental pollutions and 
climate. Endogenous pro-oxidants include pro-oxidants derived from 
endogenous metabolites, drug metabolites, cellular metabolism, ion flux, 
anxiety, pathophysiology and ischemia [56].These pro-oxidants may be 
present in the circulatory fluid (CF) which can induce OS in the vascular wall 
leading to vascular morbidities such as SSc-PAH and (CF) can be used to study 
the OS or vascular damage related pathophysiology of the vascular diseases. 
                                                                                                                                                                                                                                                                                    
1.9 Role of Oxidative stress in Cellular and Molecular Vascular 
Damage of SSc-PAH   
Oxidative stress (OS) has been recognized as an important triggering agent in 
inflammatory processes within the vascular wall, especially in the setting of 
systemic arterial disease [57]. OS may mediate through activation of 
mononuclear cells [58, 59] with infiltration of inflammatory cells in 
pulmonary perivascular spaces within and around plexiform lesions [60–62].  
In the vasculature of HT patients, ROS are formed in high concentrations that 
cannot be balanced by the normal protective antioxidant mechanisms 
employed by the cells, resulting in oxidative stress [64]. As a result, •O2− reacts 
with nitric oxide (NO) to produce a dramatic concentration of the toxic 
peroxynitrite (ONOO−) which stimulates a variety of negative effects on 
cellular function involving alteration in the functioning of kinases, protein 
synthesis, and redox-sensitive genes [65-67]. There exists a strong 
relationship between BP and some parameters related to OS [68]. It has been  
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shown that ROS production is elevated with the redox-dependent signaling 
amplified and antioxidant activity reduced in cultured vascular smooth 
muscle cells of arteries from hypertensive rats and humans [69, 70]. Reactive 
oxygen species (as depicted in Figure D) are known to play a significant role in 
intracellular signal transduction and trigger many growth-associated 
signaling pathways in vascular smooth muscle cells, comprising 
phosphorylation-mitogen activated protein arterial pressure (MAP) kinases 
(p38 and ERK5) and others [71-84]. ROS stimulate STATs, activate Akt by Ang 
II and activate tyrosine kinases and tyrosine phosphatases, and activate ras as 
well [71, 83]. These signaling events would lead to redox-sensitive growth in 
vascular smooth muscle cells, proliferation, hypertrophy, which eventually 
would confer to vascular wall thickening and remodeling (as depicted in 
Figure D) in hypertension [71-99]. The organization of membrane 
myofilaments poses a great impact on the integrity of vascular smooth muscle 
cell morphology and ROS can cause severe morphologic and structural 
alterations resulting in the vast damage of the cellular cytoskeleton. Thus ROS 
are involved in endothelial dysfunction, increased reactivity, and vascular 
remodeling which are the characteristic features of vascular damage in 
hypertension [104] related to SSc as well as in IPAH.                                                                                                                        
 
13 
Dr. Tulasigeri  M.Totiger 
“Cellular and Molecular Study of Vascular Damage during Systemic Sclerosis” 
PhD Thesis in Biochemistry, Physiology and Molecular Biology of PhD School in 




                                                                                                                                                                                
Figure D. Redox-dependent signaling pathways in vascular smooth muscle cells. Intracellular reactive oxygen species 
(ROS) modify the activity of protein tyrosine kinases (PTK), such as Src, Ras, JAK2, Pyk2, PI3K, and EGFR, as well as 
mitogen-activated protein kinases (MAPK), particularly p38MAPK, JNK and ERK5. These processes probably occur  
through oxidation/reduction of protein tyrosine phosphatases (PTP), which are susceptible to oxidation and inactivation 
by ROS. ROS also influence gene and protein expression by activating transcription factors, such as NF-nB, activator 
protein-1 (AP-1) and hypoxia-inducible factor-1 (HIF-1). ROS stimulate ion channels, such as plasma membrane Ca2+ and 
K+ channels, leading to changes in cation concentration. Activation of these redox-sensitive pathways results in numerous  
cellular responses which, if uncontrolled, could contribute to hypertensive vascular damage.ECM, extracellular matrix; 
MMPs, matrix metalloproteinases; TIMP, tissue inhibitor of matrix metalloproteinase. Tamara M and R.M.Touyz .Redox 
signaling in hypertension. Cardiovascular Research 71 (2006) 247 – 258.  
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1.10 Role of Oxidative Stress in Vascular Remodeling in SSc-
PAH 
Vascular remodeling is an active process of structural change that relies on 
active interactions between local growth factors, vasoactive substances, and 
hemodynamic stimuli and is an active process that arises in retort to 
longstanding changes in hemodynamic conditions and leads to the 
pathophysiology of vascular diseases. It is well documented that OS plays 
significant role in Vascular Remodeling in SSc-PAH. During this process, the 
arterial system endures structural remodeling that involves hypertrophy of 
the arterial wall and increased wall-to lumen ratio and accompanying 
decreased arterial distensibility. The stage when the remodeling process 
develops maladaptive, it carries further vascular damage followed by 
impaired endothelial function, enhanced reactivity, and vascular 
inflammation. In the condition of hypertension, OS promotes VSMC 
proliferation and hypertrophy, collagen deposition, and alterations in activity 
of MMPs, which results in thickening of the vascular media and arterial 
remodeling [103]. It has reported that Superoxide anion and H2O2 excite 
several growth factor-like cellular responses, such as intracellular 
alkalinization, MAP kinase phosphorylation, and tyrosine kinase activation 
[71]. In hypertension, OS not only influences arterial structure, media 
thickening but also eventually influences & affects complete vessel redox 
state. So vascular wall thickening increases the distance required for diffusion 
of oxygen from the lumen. With this, there would be a reduced pO2, which 
results in incomplete oxidation and increased concentrations of free radicals 
and abnormalities of the oxidant state. With this overall excess of OS state in 
hypertension, would further lead to vascular smooth muscle cell growth, 
endothelial dysfunction, and over-all vascular damage [104]. This would lead 
to progressive increase in pulmonary vascular resistance, pulmonary arterial 
pressure, and right ventricular (RV) pressure overload. Initially,  
15 
Dr. Tulasigeri  M.Totiger 
“Cellular and Molecular Study of Vascular Damage during Systemic Sclerosis” 
PhD Thesis in Biochemistry, Physiology and Molecular Biology of PhD School in 
Biomolecular and Biotechnological Sciences, University of Sassari 
 
 
                                                                                                                                                         Introduction 
compensatory mechanisms in the right ventricle preserve the stroke volume 
and cardiac index, but as the limits are crossed, cardiac failure and death 
follow. 
 
1.11 Involvement of NOX in SSc-PAH  
The activation of vascular NAD (P) H Oxidase plays a pivotal role in vascular 
functional and structural changes for the development of hypertension [67]. 
The NOX1 (NADPH oxidase 1) and NOX2 oxidases are the major sources of  
 
Figure E. NADPH oxidase(NOX)  a major component  involved in generation of ROS, leading to OS, Vascular 
Remodeling  & Vascular Damage in SSc-PAH {Ana Fortuno et al. Oxidative stress and vascular remodeling. Exp 
Physiol 90.4 pp 457–462(2005)}. 
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ROS in the artery wall in hypertension as well as in SSc-PAH, and thus are                                                                                                                                   
formed to be important contributors [63] to the oxidative stress that would                                                                                                                                      
lead to vascular damage[105-108]even in the premature stages[109, 110] of 
vascular disease. The abnormal vasoconstriction in the vascular wall by 
hormones, such as endothelin-1, angiotensin II, or urotensin II is mediated by 
ROS [111] produced, majorly by NOX2.ROS derived from NOX isoforms, in 
particular NOX2 and NOX4, are evident to be involved in long-term responses 
of the pulmonary vasculature to hypoxia [112-115]. NOX2 is involved in 
hypoxia induced endothelial dysfunction in the intrapulmonary arteries  
[115].Increased level of NOX was documented in the pulmonary artery 
smooth muscle cells (PASMCs) in hypoxia dependent development of PAH in  
mice [113]. As illustrated in the above Figure E, NOX more specifically NOX2, 
by generating ROS, contribute to the narrowing of the arterial lumen and 
consequently to increased peripheral resistance and blood pressure, thus 
leading to Hypertension in SSc patients.                                                                                                                                   
                                                                                                                                   
1.12 Involvement of ERK in Collagen Synthesis in SSc-PAH 
There are many signaling pathways involved in the regulation & synthesis of 
Collagen. The MAPK/ERK pathway is one of the predominant one among them 
[116,117].In both the vasoconstriction and vascular smooth muscle cell 
growth, extracellular signal-regulated kinase (ERK) is involved, which is a 
member of the mitogen-activated protein kinase family [118]. From the 
reports of hypertension in animal models, it has been showed that ERK 
activity is raised in vascular smooth muscle cells, and inhibition of ERK 
activation reduces both vascular smooth muscle cell growth and 
vasoconstriction [118,119]. ERK1 and ERK2 are the extensively explored, 
even though other isozymes of ERK are present. Activation of ERK can happen 
through stimulation of either a G protein-coupled receptor or a growth factor  
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receptor, and this can be followed by activation of the Ras, Raf, mitogen-
activated protein kinase pathway [118, 119]. There are evidences which 
reveals that, activation of ERK through G protein-coupled receptors can 
happen (as shown in Fig: F) through direct activation of the Ras, Raf, or 
mitogen-activated protein kinase pathway, or through transactivation of a 
growth factor receptor, such as EGFR. This might happen through activation of 
a matrix metalloprotease and succeeding cleavage of a membrane-bound 
ligand such as heparin-binding epidermal growth factor (EGF), leading to 
release of the ligand and activation of the receptor. In other way, activation of 
the G protein-coupled receptor could lead to tyrosine phosphorylation of the 
epidermal growth factor receptor [118]. However, there are few evidences 
suggesting that ERK activation occurs via ROS, but the mechanism needed to 
be elucidated [120].  
 
Figure F. Schematic diagram summarizing the potential mechanisms of extracellular signal-regulated kinase 
activation. Richard E Roberts. The extracellular signal-regulated kinase (ERK) pathway: a potential therapeutic 
target in hypertension. Journal of Experimental Pharmacology Aug.2012. 
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It has been shown that activation of ERK is linked with changes in gene 
transcription and cell proliferation [118]. Activated (as shown in Fig: F) ERK is 
known to be involved in Collagen synthesis and has been reported in various 
types of cells including VSMCs. 
 
Figure G: Schematic diagram summarizing the effect of extracellular signal-regulated kinase on vascular 
smooth muscle cell growth and proliferation through effects on gene transcription. Richard E Roberts 2012. 
 
Undeniably, changes of primary vascular smooth muscle cells from a 
contractile to a proliferating phenotype are associated with prolonged ERK 
activation [118] and the accompanying synthesis of collagen. This could 
progress the disease conditions such as IPAH, SSc-PAH and stenosis in which 
there is elevation in vascular smooth muscle cell growth, collagen synthesis 
and subsequent aberrant vascular remodeling (hypertrophy or hyperplasia).                    
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CHAPTER 2. AIM OF THE WORK 
An important note to assign SSc straight to vascular morbidity is because the 
vascular bed is a primary site of injury [32, 38, 44, 48, 121], and diffuse 
devascularization of multiple tissues is the major consequence. Hence, SSc is 
termed as Vascular Disease. Even, the course of the pathogenesis clearly 
shows the mode of vascular complications that line from the onset of the 
disease till late clinical manifestations. Raynaud phenomenon (RP) is 
observed in all most all SSc patients & is one of the earliest symptoms seen in 
SSc patient. When looked at cellular level, it is the clinical manifestation that 
involves abnormal functioning of cutaneous vessels that happens due to the 
thermal regulation of blood flow [122-124]. RP occurs before the onset of 
clinical signs of tissue fibrosis. The vascular abnormalities that begin & 
participate in this disease condition have prompted to better understand the 
disease course from the vascular point of view, which could help in finding out 
cellular & molecular hints that set the vascular damage during systemic 
sclerosis. Pulmonary involvement occurs in at least two thirds of systemic 
sclerosis patients and about 10-15% of them will develop severe lung disease 
during the course of their illness. Pulmonary disease has surpassed renal 
disease and is now the leading cause of death amongst patients with 
scleroderma [34, 44, 45]. It is estimated that 80% of patients with SSc have 
some evidence of pulmonary disease. The estimated mortality of pulmonary 
disease from all causes is said to be 33% [34, 35, 41]. Moreover, pulmonary 
involvement has a poorer prognosis [39]. Pulmonary arterial hypertension 
(PAH) is a grimly progressive life-threatening & a serious condition which 
prematurely takes a toll on many lives. Systemic sclerosis-related pulmonary 
arterial hypertension (SSc-PAH) is a major complication of both limited and 
diffuse systemic sclerosis that leads to substantial morbidity & mortality. SSc-
PAH has emerged as a leading cause of death [38, 44]. These are some of the 
reasons that have prompted us take up this study. In vascular smooth muscle 
cells, it has been shown that there was an elevation in protein tyrosine kinase                                                                                                                               
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activity and tyrosine phosphorylation in response to cooling and are linked to 
excessive alpha2-adrenergic response and shown that  increased level ROS 
activate of Rho/Rho kinase pathway and up-regulates alpha2c-adrenergic 
receptors on the surface of vascular smooth muscle cells, thus determining an 
excessive vasoconstrictive response to cooling [122-124] and clearly showing 
that ROS[52] are involved in the early pathogenesis. Structural alterations of 
small and medium-sized arteries contribute to RP involving Smooth muscle 
cells & endothelial cells, thus leading to Vascular remodeling as result of 
deposition of extracellular matrix (ECM) and fibrosis. These above mentioned 
participations of SMCs prompted us to use this type of cells as an ideal cell 
model to study SSc-PAH. In hypertension, OS besides influencing arterial 
structure, media thickening, also eventually influences & affects complete 
vessel redox state [125,126]. Hence, vascular wall thickening would lead to 
increase in the distance required for diffusion of oxygen from the lumen thus 
resulting in reduced pO2, which leads to incomplete oxidation and increased 
concentrations of free radicals and abnormalities of the oxidant state [52]. 
This overall excess of OS state in hypertension, would further lead to vascular 
smooth muscle cell growth, endothelial dysfunction, and over-all vascular 
damage [125,126].Many circulating factors have been shown to be associated 
in the pathogenesis of Raynaud’s phenomenon related to SSc, involving in 
platelet activation, impaired fibrinolysis, white blood cell activation, reduced 
red blood cell deformability and oxidative stress [122,127]. Due to OS, there 
occurs an unbalanced redox homeostasis, and circulatory factors may contain 
the endogenous derived factors which can exhibit the pathophysiology state 
that is caused by the OS. Thus the circulatory factors play very significant 
roles in the assessment of SSc-PAH, wherein they could be used to study the 
pathophysiology that has been exerted by OS. In such condition the blood as 
the circulatory fluid may have ROS or free radicals or pro-oxidant factors, 
activated growth factors, cytokines or molecules in it, which may direct in  
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activating the pulmonary arterial smooth muscle cells, endothelial cells or the 
complete vascular bed with the wrong signals formed by the abnormality 
caused by OS or other factors. From previous reports, it is well evident that                                                                                                                                 
NOX are the major contributors of ROS in the vascular wall. It has been shown 
that NOX2 subunit involved in generation of large amounts of ROS, and so 
inhibiting or deleting NOX2 or p47phox subunits significantly reduced 
vascular oxidative stress in several disease models [106, 129-136]. So there is 
a strong rationale for therapeutically targeting NOX2 oxidase in the arterial 
wall for the treatment of vascular disease such as SSc-PAH, so as to combat the 
oxidative stress and prevent the progression of vascular disease such as SSc-
PAH.It is has been suggested that the high mortality in SSc-PAH may be due to 
excessive collagen content in the heart and the pulmonary arteries [137]. 
Vascular collagen content has impact on hemodynamics of SSc-PAH, which is 
due to the overproduction of collagen throughout the body. However, it has 
been reported that excessive PA collagen accumulation is linked to increased 
PA stiffening and has been shown that excessive PA(Pulmonary 
Artery)collagen accumulation elevates (pulmonary vascular impedance) PVZ 
or right ventricular afterload [138-142]. So, whether sera of SSc-PAH 
stimulate collagen synthesis has become one of the objectives of this study.  
From the reports it is known that MAPK/ERK is the predominant pathway 
involved in the regulation & synthesis of Collagen and there are evidences 
reporting that ERK activation occurs via ROS [120] but the mechanism is not 
clearly understood. ERK signaling contributing to the overexpression of pro-
fibrotic proteins in scleroderma fibroblasts as well as VSMCs is unclear. 
Hence, targeting ROS and as well as collagen synthesis by inhibiting ERK or 
ROS-mediated ERK could potentially be an important pharmacological 
treatment of hypertension in SSc. By gathering the above background, it can 
be explained collectively, that OS is involved in the Vascular Damage of SSc-
PAH. This leads to the state of unbalanced redox homeostasis and generate 
large amount of ROS by stimulating growth factors & cytokines. These factors    
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may be present in the circulatory fluid and can be detected and their effect can 
be analyzed in in-vitro. This ligand stimulated change in the cellular redox 
state could lead to vascular remodeling characterized by VSMC hypertrophy & 
hyperplasia and ECM deposition leading to subsequent Obliterative 
Vasculopathy. Hence, it can be hypothesized that in SSc patients associated 
with Pulmonary Arterial Hypertension (PAH), circulating factors may drive an 
aberrant vascular remodeling by exerting pro-oxidant & Pro-fibrotic effects on 
Pulmonary Arterial Smooth Muscle Cells (PASMCs) and activate collagen I 
synthesis. 
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CHAPTER 3. MATERIALS AND METHODS 
 
3.1. Materials 
Smooth Cell medium was purchased from ScienCell Research Labs, Fetal 
Bovine Serum (FBS) purchased from Invitrogen, rat tail Collagen I coating 
agent, ERK Inhibitor PD98059, DMEM were purchased from Sigma-Aldrich, 
GFP-based Lentiviral Particle (harboring the COL1A1 promoter having 
COL1A1-LV-tGFP and EF1α-LV-FP602) was initially purchased from Innoprot- 
Innovative Technologies In Biological Systems, S.L. But the production of the 
same Lentiviral particles was done by purchasing second generation 
packaging systems from Addgene,Inc. 2‟,7‟-dichlorodihydrofluorescein 
diacetate (H2DCF-DA) (Molecular Probe) was purchased from  Eugene, 
OR.NOX NOX2ds-tat was purchased from Anaspec (Fremont, CA, USA) . 
 
3.2      Cell culture and treatments. 
Human Pulmonary Artery Smooth Muscle Cells (HPASMCs) purchased   from 
Innoprot-Innovative Technologies In Biological Systems, S.L. The cell line was 
supplemented with specific medium(Smooth Cell medium, ScienCell). The cell 
culture was done by using rat tail Collagen I as a matrix or coating agent to 
promote adherence and attachment to provide proper cell growth. When 
cultured HPASMCs reach confluent stage, they were split in to 1:2 ratio and 
the cells were used for experiments with passage numbers below six. In 
routine maintenance of HPASMCs, during splitting of cells, the neutralization 
is done to stop trypsinization by using Neutralization Solution and Fetal 
Bovine Serum (FBS) in the ratio of 1:1.Experiments were done by plating 
required number of HPASMCs in 96-well black plates and white plates (BD 
Falcon, Franklin Lakes, NJ.  
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For measuring intra cellular ROS 10 μM of H2-DCFDA (Figures 1A & 1B) was 
used prior to stimulation by sera and the intra cellular ROS was measured 
kinetically for 4hrs. 
In the experiments for measuring the collagen promoter activity(Figures 
2A,2B,4,6), the cells were transduced with lentiviral particles obtained from 
the COL1A1-LV-tGFP and EF1α-LV-FP602 lentivectors, and then cultured in 
basal medium for stimulating the cells with sera and COL1A1 promoter 
activity were kinetically measured for 10 hours. 
In the experiments (Figures 3, 4) for studying NOX involvement, HPASMCs 
were incubated for 1 hour with 5 μM NADPH oxidase specific inhibitor 
NOX2ds-tat (NOX) before treatment with SSc sera. 
In the experiments (Figures 5, 6) for studying ERK involvement, HPASMCs 
were incubated for 1 hour with 15 μM of PD98059, a specific inhibitor of ERK 
before treatment with SSc sera. 
 
3.3 Study Subjects. 
Study subjects were enrolled by signing the informed consent and the 
collected data of clinical, serologic, and diagnostic criteria were according to 
the protocol approved by the Johns Hopkins Scleroderma Center Baltimore, 
Johns Hopkins University’s Institutional Review Board (IRB). Through posted 
flyers, Healthy donors (HD) were recruited and enrolled after going through 
such a screening questionnaire that aimed at excluding the presence of any 
underlying vascular or autoimmune disease. Each SSc patient met the 
American College of Rheumatology criteria or had 3 of 5 features of the CREST 
(Calcinosis, Raynaud’s syndrome; Esophageal dysmotility; Sclerodactyly; 
Telangiectasia) syndrome [143]. Each Patient’s demographic profile, SSc  
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subtype, autoantibody status, Medsger severity scores, pulmonary function 
tests, echocardiography, and right heart catheterization parameters, modified 
Rodnan skin scores(mRSS) were assessed. Demographic data comprising sex, 
race, smoking status (never, past current) were also evaluated. Calculation of 
SSc disease duration was done at the time of serum sampling, by counting the 
years from the onset of RP or from the first non-RP symptom. RP, heart and 
lung severity scores were evaluated as previously defined by Medsger et al 
[144]. 
  
3.4 Measurements of Intracellular ROS 
Intracellular ROS levels were measured by using the ROS molecular probe 
2‟,7‟-dichlorodihydrofluorescein diacetate (H2-DCFDA). Esterases cleave the 
acetate groups on H2-DCFDA within the cell, consequently trapping the 
reduced form of the probe (H2DCF). Intracellular ROS oxidize H2DCF, yielding 
the fluorescent product, DCF. When HPASMCs reach sub-confluent were 
loaded with 10 μM of H2-DCFDA. Then washed with PBS1X buffer followed by 
treatment with 5% (V/V) of sera from scleroderma (SSc) patients with 
pulmonary arterial hypertension (PAH), without PAH(No PAH) and healthy 
donors (HD)respectively in basal medium. Intracellular ROS levels were 
kinetically measured using GENios plus microplate reader (Tecan, Männedorf, 
CH) with excitation at 485 & emission at 535  respectively in a 4 hour time-
course experiment (Figure 1A) and values at 2 hours (steady state) used for 
comparison (Figure 1B). Fluorescence measurements were corrected for 
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3.5 GFP-based Lentiviral Particle (harboring the COL1A1 promoter) 
Production. 
Lentiviral vectors (LV) are very efficient (can exceed 90%) at transferring 
viral DNA into host cells and integrate stably into the host-cell genome of 
dividing and non-dividing cells and  can provide long-term expression  of the 
vectored transgene in target cells and thus provide great potential for gene 
therapeutic applications [145-148 ]. Because of these advantages we 
employed lentiviral vectors as shown below (Fig .H & I) in our study. The 2nd 
generation system plasmids are less bulky to use and highly efficient and have 
ease of use over third-generation system led us to use these in our study.  
 
Figure H : The vector map of LVTHM transfer vector. 
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  Description of Each Component of the Vector Map: 
5’LTR 5’ Long terminal repeat, contains cis regulatory regions which recruit 
proteins that promote transcription of full length lentivirus.Sequences here 
facilitate proviral integration into the host genome; an intact 5’LTR indicates 
that this is a 2nd generation transfer plasmid 
Psi Sequence that facilitates packaging of viral RNA 
RRE Rev response element: sequence to which the Rev protein binds to 
facilitate nuclear export of viral RNA 
EF1α Promoter for elongation factor 1α, used to the expression of a marker 
gene such as GFP 
cPPT Central poly purine tract allows nuclear import of lentivirus in host cells 
 
GFP Green fluorescent protein used to mark successfully infected cells 
 
WPRE The woodchuck hepatitis virus Posttranscriptonal response element 
augments shRNA expression 
 
TetO Binding site for the tet repressor protein or a variant thereof which can 
be used to turn on or off shRNA expression 
 
H1 Histone H1 promoter used to drive shRNA expression 
 
LoxP Site which is recombined by the Cre recombinase in order to 
conditionally remove the lentiviral provirus from the host genome after 
successful infection and incorporation 
 
3’LTR/SIN 3’LTR with a large deletion in the U3 region, makes the virus 
replication incompetent 
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C) Map of Human α(I) Procollagen Gene Promoter-Lentiviral vector-tGFP 
LentiFP602: These lentiviral particles express FP602 red fluorescent protein 
under the EF1a promoter. This promoter is not tissue specific and highly 
expressed in all cell types. 
 
LentipCOL1A1tGFP: These lentiviral particles express tGFP green fluorescent 
protein under the collagen type1 promoter (-804+42). This promoter is tissue 
specific and expressed in smooth muscle cell types. 
 
Figure I : Map of Human α(I) Procollagen Gene Promoter-Lentiviral vector-tGFP. 
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By using the above shown 2nd generation plasmids containing COL1A1-LV-
tGFP and EF1α-LV-FP602 lentivectors, the co-transfection into human 
embryonic kidney 293T cells was done , and then the medium was collected 3 
times at 24 hour intervals beginning 24 hours after changing the medium 
post-transfection. Thus lentiviral particle production was done by using 293T 
cells [149, 150] as described. Later purification process was performed. In this 
step, every sample was filtered immediately through a 0.22 mm cellulose 
acetate filter and stored at 40 C. The virus pellet was collected by carrying out 
2hrs of ultracentrifugation at 19.4K rpm and at room temperature. Since 
lentiviral particles contain GFP as a reporter system, transfection was 
confirmed by using Fluorescent microscopy and then titration of lentiviral 
vectors was performed. 
 
3.6 GFP-based Lentivirus (harboring the COL1A1 promoter) 
Transduction in HPASMCs. 
The lentivirus transduction was done in HPASMCs by following the company 
protocol (Innoprot- Innovative Technologies In Biological Systems, S.L.). The 
determined number of HPASMCs were seeded in Smooth Muscle Cell complete 
medium and incubated overnight. When 50%-75% confluent,the lentiviral 
stock was thawed at room temperature. The culture medium was then 
removed and appropriate amount of this virus stock was loaded to cells and 
the required volume of the medium was bought by using OptiMEM. The cells 
were then placed in the CO2 incubator maintained at 5% CO2 and 37oC and the 
plate was carefully rotated for every 15 min for 1 hour. Later Smooth Muscle 
Cell complete medium was added to bring to the required volume. At around 
48-72h after transduction, the Green Florescent protein production or 
expression was checked under fluorescence microscope. 
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3.7 Measurement of COL1A1 Promoter Activity 
 HPASMCs transduced with lentiviral vector were treated with of 5% (V/V) of 
sera from PAH, no PAH and HD subjects in basal medium. The kinetic 
measurement COL1A1 promoter activation was performed for 10 hours 
(Figure2A) and any deviations occurred during this course of time was 
studied. The steady state in the promoter activation was attained at 8hrs and 
the values at this time point were used for comparison (Figure 2A, 2B, 4, 6) 
and data were normalized for transduction efficiency by reporting the ratio of 
COL1A1-LV-tGFP to EF1α-LV-FP602 Relative Fluorescence Units (RFU). 
 
3.8 Study of NOX Involvement. 
HPASMCs were pretreated with 5 μM NADPH oxidase specific inhibitor 
(NOX2ds-tat, formerly gp91ds-tat) [151] for 1hr before stimulating with sera 
from PAH, no PAH and HD subjects and Intracellular ROS was then measured( 
as shown in Fig.3) as previously described to observe the NOX inhibitor 
effect.HPASMCs transduced with lentiviral vector (obtained from the COL1A1-
LV-tGFP and EF1α-LV-FP602) were incubated for 1 hour with 5μM of NOX 
before treatment with SSc sera from the three subjects (PAH, no PAH and HD). 
Then collagen type-I (COL1A1) promoter activity was measured (as shown in 
Fig.4) as previously described to determine whether NOX inhibitor has effect 
on collagen promoter activity. 
 
3.9 Study of ERK Involvement 
For studying the effect of ERK inhibitor PD98059 on Intracellular ROS, 
HPASMCs were pretreated with 15μM of ERK inhibitor PD98059 for 1hr 
before stimulating with sera from PAH, no PAH and HD subjects and  
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Intracellular ROS was then measured as described earlier.                                                                                                                       
In another set of experiments for studying the effect of ERK inhibitor 
PD98059 on COL1A1 promoter activity, HPASMCs were pre-incubated with 15 
μM of ERK inhibitor PD98059 for 1hr before stimulating with sera from PAH, 
no PAH and HD subjects and collagen I synthesis was assessed as described 
earlier to observe the effect of this inhibitor. 
 
3.10 Statistical Analysis 
Healthy donors were matched for gender, race and smoking status. Horizontal 
lines indicate the median with interquartile range (Fig1A,2A). Kruskall–Wallis 
one-way analyses of variance followed by post-hoc Dunn’s test for multiple 
comparisons were used to detect differences among studied groups in (Fig 1B, 
2B). For studying subjects’ characteristics, P values were determined by 
Fisher’s exact test or the Wilcoxon rank-sum test, as appropriate. Wilcoxon 
matched-pairs signed rank test was used to determine meaningful differences 
between pre- and post-NOX & ERK inhibitor treatment pairs in Figures 3, 4, 5 
& 6. All statistical analysis were performed using GraphPad Prism version 
6.00 for Windows (GraphPad Software, San Diego, CA) and p-values <0.05 
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4.1 Demographic Data and Clinical Characteristics of Subjects: 
 
Mainly the middle age, white women were the SSc patients enrolled in this 
study. SSc subjects were concluded as “No PAH” (n = 17) if their right 
ventricular systolic pressure (RVSP) estimated by echocardiogram was ≤35 
mm Hg, and they were defined as “PAH” (n = 19) if the RVSP was >35 mm Hg. 
They underwent right heart catheterization (RHC) showing a mean 
pulmonary artery pressure (mPAP) ≥ 25 mm Hg and pulmonary capillary 
wedge pressure (PCWP) ≤ 15 mm Hg. For this study, Healthy Donors [HD] (n = 
14) were selected through such a screening questionnaire, so as to rule out 
any underlying autoimmune or vascular disease in the donors. In this study, 
patients with PAH were slightly older than No-PAH (64.0 ± 9.4 vs 53.3 ± 11.6; 
p = 0.009) and had longer disease duration (18.5 ± 9.5 vs 10.5 ± 7.3 years; p = 
0.01). These observations matched with most of the reports saying that PAH 
occurs as late age manifestation in SSc [152-156]. It was also registered that in 
this study, there was slight elevation in modified Rodnan skin score( mRSS) in 
SSc-PAH patients as compared to No-PAH  (7.3 ± 10.3  vs  5.5 ± 6.1;p=0.567) 
pin pointing there was  no significant difference in the values of  mRSS  
between the  comparable subjects. RP severity scores (1.6 ± 0.8 2.0 ± 1.0; p= 
0.194) and Heart severity scores (0.2 ± 0.7 1.2 ± 1.7; p=0.062) were little bit 
higher in SSc-PAH vs No-PAH, but not reaching to the significant difference 
between the subjects. But as anticipated, SSc-PAH subjects revealed relatively 
higher lung severity scores (3.1 ± 1.3 vs 1.1 ± 1.3; p < 0.001) against No-PAH 
subjects. Cardiac hemodynamic measurements by Right heart Catheterization 
showed that mean pulmonary arterial pressure (mPAP) values (35.2 ± 8.1 mm 
Hg) and pulmonary capillary wedge pressure (PCWP) values (11.5 ± 4.0 mm 
Hg) were remained in the range as expected to be in SSc-PAH subjects as 
defined by mPAP should be ≥25 mm Hg, as well as PCWP should be ≤ 15 mm  
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Hg to diagnostically characterize the individuals having PAH according to the                                                                                                                                                  
reports [17,157]. These diagnostic measurements clearly provided the proof 
that severe abnormalities were present in the structural & functional mode of 
pulmonary vascular compartment. It was observed that there was 
significantly lower diffusion capacity of lung for carbon monoxide (DLCO) 
(48.7 ± 16.8 vs 78.2 ± 23.0; p < 0.001) with comparable forced vital capacity 
(FVC) with decreased values against No-PAH subjects, which provided the 
confirmed clues that there exists an underlying pulmonary vascular disease. 
Pulmonary function tests (PFT) revealed that values determining restrictive 
lung disease (RLD) remain equal in both the subjects. In this study, it was 
observed that SSc-PAH patients exhibited significantly higher estimated right 
ventricular systolic pressure (ERVSP) values (65.2 ± 19.9 vs 24.0 ± 6.3; p= 
<0.001) against those of Non-PAH subjects. This elevated value of ERVSP 
further clarified the devastating damage of pulmonary vascular function of 
this ailment and also the severity of the underlying pulmonary vascular 
disease. ERVSP values  >30–45mmHg are often considered abnormal  even 
though there are no consensus about the elevated levels of healthy individuals 
but  ERVSP values  generally does not increase in normal individuals. Studies 
have been reported that SSc patients having ERVSP >35mmHg showed 
elevated pulmonary pressures [158,159], thus proving the underlying 
impairment in pulmonary vascular compartment. Another study also 
confirmed that combination of eRVSP on TTE and PFT parameters provided in 
identifying of up to 97–100% of SSc patients with RHC confirmed PAH 
[160].The antibody status in this study revealed that SSc-PAH subjects 
showed not though significant but slight higher level of Anti centromere 
antibodies {(ACA) 10 (53) vs 4 (24); P= 0.07} which have been put very 
relevant to the underlying cause of PAH in SSc by the earlier reports. 
Demographic Studies have shown ACA is prevalent in older, female 
Caucasians having SSc, so the same case in this study as well. It has been 
reported that the presence of ACAs linked with higher risk of development of  
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PAH [161,162] in SSc patients particularly the lSSc patients [161]. Anti-Scl-70 
(anti-topoisomerase I) antibodies in this study were found lower in SSc-PAH 
against the No-PAH subjects as this study includes SSc-PAH subjects mostly 
from lcSSc subjects and Anti-Scl-70 are mostly found in patients with dcSSc 
having pulmonary involvement, more specifically linked to pulmonary fibrosis 
& interstitial lung disease [161,163,164]. The medications used by this study’s 
subjects were vasodilators (i.e. endothelin receptor antagonists and 
phosphodiesterase 5 inhibitors) which were significantly higher in SSc-PAH 
subjects.  
Variables                                                                 No PAH (N = 17)      PAH (N = 19)       HD (N = 14)    p value• 
Age at serum sampling (years)*                           53.3 ± 11.6            64.0 ± 9.4              54.1 ± 10.4          0.009  
Female                                                                       15 (88)                   16 (84)                    15 (85)                 0.727 
Race 
White                                                                         14 (82)                   16 (84)                    12 (80)                0.881 
Black                                                                            3 (18)                     3 (16)                      3 (20) 
Smoking status  
  Never                                                                        9 (53)                      10 (53)                    8 (53)                 0.280 
  Past                                                                           6 (35)                        9 (47)                    5 (33) 
Current                                                                       2 (12)                         0                           2 (13) 
SSc types 
Limited                                                                      11 (65)                      16 (84)                                               0.177 
Diffuse                                                                         6 (35)                      3 (16) 
mRSS* (range 0–51)                                               5.5 ± 6.1                 7.3 ± 10.3                                            0.567 
SSc duration (RP onset)*, years                         14.0 ± 12.6            21.7 ± 9.4                                               0.008 
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SSc duration (1st non-RP symptom)*, years   10.5 ± 7.3               18.5 ± 9.5                                               0.010 
RP severity score* (range 0–4)                             1.6 ± 0.8                2.0 ± 1.0                                               0.194 
Heart severity score* (range 0–4)                        0.2 ± 0.7                1.2 ± 1.7                                               0.062 
Lung severity score* (range 0–4)                          1.1 ± 1.3               3.1 ± 1.3                                             <0.001 
Hemodynamics (RHC) 
mPAP* (mm Hg)                                                        NA                       35.2 ± 8.1                                              NA 
PCWP* (mm Hg)                                                        NA                       11.5 ± 4.0                                              NA 
FVC* (% predicted)                                                 81.9 ± 22.9           73.1 ± 9.9                                              0.149 
DLCO* (% predicted)                                             78.2 ± 23.0            48.7 ± 16.8                                         <0.001 
RLD†                                                                            6 (35)                      6 (32)                                                  0.813 
eRVSP*                                                                     24.0 ± 6.3               65.2 ± 19.9                                        <0.001 
Autoantibody status 
ACA                                                                            4 (24)                      10 (53)                                                  0.07 
Anti-Scl-70                                                                7 (41)                        1 (5)                                                    0.01 
Anti-RNA-polymerase 3                                         2 (12)                         0                                                         0.124 
Medication use (current) 
Immunosuppressants‡                                           5 (29)                      5 (26)                                                   0.836 
Calcium channel blocker                                     10 (59)                       7 (37)                                                   0.187 
Endothelin receptor antagonist                             1 (6)                       6 (32)                                                   0.052 
Phosphodiesterase 5 inhibitor                               4 (24)                   11 (58)                                                   0.037 
Prostanoid                                                                  0                             0                                                           NA 
Statin                                                                           6 (35)                     5 (26)                                                  0.559 
Aspirin                                                                         5 (29)                     5 (26)                                                  0.836 
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Table A.  Statistical Data and Clinical Characteristics of Subjects having SSc-PAH, SSc-No PAH & Healthy 
Donors. All values are given as number (%) unless otherwise specified. *Mean ± SD. †The presence of RLD 
was defined by a FVC < 70% of predicted. ‡Use of immunosuppressants include cyclophosphamide, 
mycophenolate, methotrexate, hydroxycholorquine or prednisone. §P values were determined by Fisher’s 
exact test or the Wilcoxon rank-sum test, as appropriate.  
 
4.2 Exposure of subjects ‘sera to Human Pulmonary Arterial Smooth 
Muscle Cells (HPASMCs) and Kinetic Measurement of Intracellular ROS 
The figure below (Fig1A) depicts the Kinetic Measurement of Intracellular 
ROS in HPASMCs. All the three subjects’ sera were used in this experiment to 
observe whether they could induce generation of ROS. For this, the HPASMCs 
were exposed to sera {5% (V/V)} and kinetic measurement of intracellular 
ROS was followed for the duration of 4hrs.Intracellular ROS generation was 
studied in HPASMCs in response to the exposure of sera using 2‟,7‟-
dichlorodihydrofluorescein diacetate (H2-DCFDA) and this probe enters the 
cells and get oxidized in the presence of ROS, generating the fluorescent 
compound, DCF.This result showed that SSc-PAH subjects’ sera stimulated 
generation of intracellular ROS with higher level as compared to No-PAH 
subjects and no response was exhibited by Healthy Donors (HD) sera. As 
anticipated  by a ligand-stimulated ROS activation, a rapid and sustained raise 
in the intracellular ROS levels were observed starting from the cells exposure 
to the sera (Time =0). The sera-induced raise of ROS was spiked at around 30 
minutes, thereafter a gradual and slow decrement was visible, which is 
consistent with a redox-regulated signaling event. These dramatic differences 
in the intracellular ROS levels were noted down and they acquired the steady 
state from the time point of 2hrs and followed the steady state till the end 
time point of 4hrs of this experiment as shown in Fig 1A.Previous reports 
demonstrated that serum factors in-vitro induced ROS production in vascular 
cells [166]. Following the same response, this experiment revealed that sera 
of SSc of both the subjects (SSc-PAH and No-PAH) have factors that could  
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stimulate and induce intracellular ROS generation in vascular cells such as 
HPASMCs against the lack of response to (HD) Healthy Donors’ sera. This 
result provided the clue that some factors might be present in the sera of SSc 
subjects which might be pro-oxidant factors but earlier reports showed that 
platelet activation, impaired fibrinolysis, white blood cell activation, reduced 
red blood cell deformability and oxidative stress [122,127] are involved and                                                                                                                                            
all of these circulatory factors have been implicated in the pathogenesis of 
Raynaud’s phenomenon and so in the development of SSc disease phenomena. 
Since there was intracellular ROS generation in our context of this experiment, 
when HPASMCs were exposed to SSc sera, driven the clue that pro-oxidant 
factors (OS) might be involved in the induction and generation of intracellular 
ROS in HPASMCs. In order to draw the comparison between the subjects at 
this steady state (2hr Time Point), statistical analysis at this time point was 
done as shown in the Figure.1B to confirm that indeed pro-oxidant factors 
(OS) are involved in SSc-PAH and No-PAH subjects. Sera of SSc-PAH 
individuals showed that the generation of intracellular ROS in HPASMCs was 
significantly higher against the No-PAH and Healthy Donors (HD) with median 
(interquartile range) of 213 (158) compared to subjects without PAH [141 
(48); p = 0.027] and HD[130 (52); p = 0.002].  But when it was compared 
between No-PAH and Healthy Donors, it was revealed that the induction of 
intracellular ROS by sera of No-PAH is increased against the sera of healthy 
donors but was not to significant enough to draw the comparison. This result 
showed that SSc-PAH sera had pro-oxidant effect on HPASMCs by inducing the 
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Figure 1A:Kinetic Measurement of Intracellular ROS in HPASMCs exposed to Sera of SSc-PAH,SSc-
No PAH and Healthy Donors to examine the effects of SSc sera on human pulmonary artery smooth 
muscle cells (HPASMCs) intracellular ROS production. Here,sub-confluent HPASMCs were loaded 
with 10 μM of H2-DCFDA before stimulation, and then cultured in basal medium containing 5% 
(V/V) of sera of the above mentioned subjects. Variations in intracellular ROS levels were 
kinetically determined in a 4 hour time-course experiment.  
Figure 1B: Measurement of Intracellular ROS in HPASMCs exposed to Sera of SSc-PAH, SSc-No PAH 
and Healthy Donors taken at 2hr time point of steady state to look for the comparison between the 
subjects. Healthy donors were matched for gender, race and smoking status. Horizontal lines 
indicate the median with interquartile range (Fig 1A). Fluorescence data were normalized for 
protein content and expressed as Relative Fluorescence Units (RFU). Kruskall–Wallis one-way 
analysis of variance followed by post-hoc Dunn’s test for multiple comparisons was used to detect 
differences among studied groups (Figure 1B). P values =0.027 compared to No PAH and P values 
=0.002 when compared to Healthy Donors thus illustrating the significant effect of sera in inducing 
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4.3 Exposure of subjects ‘sera to Human Pulmonary Arterial Smooth 
Muscle Cells (HPASMCs) and Kinetic Measurement of COL1A1 Promoter 
Activity 
Type I collagen overproduction as ECM component is the hallmark of fibrosis 
in SSc. It is the most abundant collagen present in SSc patients compared to 
other types, with the presence of certain nucleotide repeats linked with higher 
expression of COL1A1 and COLA1A2 [165]. There are reports demonstrating 
that expression of the COL1A1 gene is primarily regulated at the 
transcriptional level and that its highest promoter activity in both normal and 
SSc fibroblasts resides in the proximal promoter region [168, 169]. And there 
is a report that showed that SSc fibroblasts produce ROS constitutively and 
this elevated ROS levels could be involved in the increased collagen 
expression in these cells [107]. VSMC is the main cell type most responsible 
for the vascular deposition of ECM proteins in hypertension [170-172] and 
this lead us the idea that whether ROS or pro-oxidant effect of sera induce 
collagen synthesis in HPASMCs.  With this back ground, we speculated to see 
whether serum factors are involved in the COL1A1 promoter activity. For this, 
the GFP based lentivirus transduction in HPASMCs was done and confirmed. 
Then sera {5% (V/V)} of all three subjects were exposed to HPASMCs and the 
kinetic measurement for 10 hrs was endured to closely observe as when the 
sera trigger the promoter activity as shown in Fig.2A. The outcome of this 
experiment showed that sera of SSc triggered a progressive time-related 
increase of the COL1A1 promoter activity with values at 8 hours remained 
steady state. By looking at the kinetic measurement lines of the three different 
subjects it was noticed that sera of SSc-PAH had more increased influence in 
activating promoter activity as compared to No-PAH. According to the kinetic 
measurement of COL1A1 promoter activity induced by sera of subjects  
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under study in HPASMCs, at around 8hrs, the COL1A1 promoter activity 
remained stable. So at this time point the comparative statistical analysis was                                                                                                                             
done to observe the significant level of COL1A1 promoter activity by all the 
three subject groups. Here, sera from SSc-PAH showed the significant level of 
increase in inducing the promoter activity in HPASMCs against the No-PAH 
subjects’ sera with values of PAH [2.375 (1.597)] compared to no-PAH [1.825 
(0.612); p = 0.028] and HD [1.844 (0.265); p = 0.007] sera. In case of No-PAH 
comparison against Healthy donors, it came to known that sera of No-PAH 
sera had increased level of COL1A1 promoter activity versus Healthy donors 
but not driving to the statistically significant values as shown in Fig.2B.The 
overall conclusion drawn from this experiment, revealed that sera from SSc-
PAH subject group significantly increased the COL1A1 promoter activity and 
hence the Collagen synthesis in HPASMCs. This experiment proved that sera of 
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Figure 2A: Kinetic Measurement COL1A1 Promoter Activity in PASMCs  transduced with COL1A1 
promoter  containing lentivirus and examination of  the effects of SSc sera on HPASMCs collagen 
(COL1A1) promoter activation. Here, the sub-confluent HPASMCs were transduced with lentiviral 
particles obtained from the COL1A1-LV-tGFP and EF1α-LV-FP602 lentivectors, and then cultured in 
basal medium containing 5% (V/V) of sera from PAH, no PAH and HD subjects. Variations of 
COL1A1 promoter activation were kinetically followed for 10 hours. Horizontal lines indicate the 





Figure 2B: Values taken at 8hr Time Point of Steady State to draw the comparison between the 
subjects. Data (Fig 1A & 1B) were normalized for transduction efficiency by reporting the ratio of 
COL1A1-LV-tGFP to EF1α-LV-FP602 Relative Fluorescence Units (RFU). Healthy donors were 
matched for gender, race and smoking status. Kruskall–Wallis one-way analysis of variance 
followed by post-hoc Dunn’s test for multiple comparisons was used to detect differences among 
studied groups. P values =0.028 compared to No PAH and P values =0.007 when compared to 
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4.4 Effect of N0X2 inhibitor gp91on Intracellular ROS 
From many reports it has been concluded that Oxidative stress plays a pivotal 
role in the pathophysiology of vascular diseases such as SSc [38, 52, 58, 64, 
66-68, 70,173]. And Reactive oxygen species are known to cause oxidative 
damage to various cells and induce organ dysfunction after ischemia-
reperfusion injury. Nicotinamide Adenine Dinucleotide Phosphate-Oxidase 
(NADPH Oxidase or NOX) form the predominant biochemical source of ROS 
in the vasculature [174-178]. The NOX1 (NADPH oxidase 1) and NOX2 
oxidases are the major sources of ROS in the artery wall  in hypertension as 
well as in  SSc-PAH, and are formed to be  important contributors to the 
oxidative stress[106-108] in SSc-PAH. Hypertension was worsened by NOX2 
overexpression in experimental models [179].So this background suggested 
us to employ NOX2 inhibitor gp91 and to target NOX2 to validate whether 
NOX2 is involved in the Oxidative damage of SSc-PAH.To test this idea, the 
HPASMCs were pre-incubated with 5 μM NADPH oxidase specific inhibitor 
NOX2ds-tat (NOX) (  formerly  called as gp91ds-tat) for 1 hour. Later, 
HPASMCs were exposed to 5% (V/V) of sera from SSc-PAH, and no PAH 
subjects. NOX2ds-tat effectively reduced induction of ROS by PAH-SSc sera (p 
= 0.009), confirming that NADPH oxidase is indeed involved in the generation 
of ROS in SSc-PAH subjects as depicted in Fig.3. When the analysis of NOX 
inhibitor NOX2ds-tat effect was tested for SSc-No-PAH sera on HPASMCs 
disclosed that there was no significant reduction in ROS levels. So from this 
result it was proved that inhibiting NOX2 could reduce the pro-oxidant effect 
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Figure 3: Effect of N0X2 inhibitor gp91on Intracellular ROS in sera stimulated HPASMCs. Here, sub-
confluent HPASMCs were incubated for 1 hour with 5 μM NADPH oxidase specific inhibitor 
NOX2ds-tat (NOX) before treatment with SSc sera {5% (V/V)} and measurement of Intracellular 
ROS in PASMCs exposed to Sera of SSc-PAH and SSc-No PAH was carried out. Fluorescence data 
were normalized for protein content and expressed as Relative Fluorescence Units (RFU).Wilcoxon 
matched-pairs signed rank test was used to draw the differences between pre- and post-NOX 
treatment pairs. P values =0.009 compared to PAH+NOX, thus illustrating the significant effect of 
N0X2 inhibitor gp91 in counteracting the intracellular ROS stimulated by SSc-PAH  sera but the 
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4.5 Effect of N0X2 inhibitor gp91 on Collagen type I COL1A1 promoter 
Activity  
In this experiment, GFP based lentivirus transduction in HPASMCs was done. 
Then HPASMCs were pre-treated with 5 μM NADPH oxidase specific inhibitor 
NOX2ds-tat for 1hr. And then, sera {5% (V/V)} from SSc-PAH and No-PAH 
subjects were exposed to transduced and NOX inhibitor treated HPASMCs and 
measured for COL1A1 promoter activity. This experiment revealed that 
NOX2ds-tat acted in very effective manner by significantly (p = 0.005) 
reducing the COL1A1 promoter activity in the SSc-PAH exposed HPASMCs, 
however there was no significant effect produced in the HPASMCs that were 
exposed to No-PAH as depicted in Fig.4.This experiment provided the result 
that NADPH Oxidase inhibitor NOX2ds-tat is also involved in the activation of 
COL1A1 promoter activity and hence in the synthesis of Collagen I in 
HPASMCs  revealing that phenotypic switch and collagen synthesis activation 
in these cells may be driven by SSc-related PAH sera through NADPH-oxidase 
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Figure 4: Effect of N0X2 inhibitor gp91on COL1A1 Promoter Activity in sera stimulated HPASMCs. 
Here,  sub-confluent HPASMCs were transduced with lentiviral particles obtained from the 
COL1A1-LV-tGFP and EF1α-LV-FP602 lentivectors, and then incubated for 1 hour with 5 μM 
NADPH oxidase specific inhibitor NOX2ds-tat (NOX) before treatment  with 5% (V/V) of sera from 
PAH, no PAH and COL1A1 Promoter Activity was measured. Data are normalized for transduction 
efficiency by reporting the ratio of COL1A1-LV-tGFP to EF1α-LV-FP602 Relative Fluorescence Units 
(RFU). Wilcoxon matched-pairs signed rank test was used to draw the differences between pre- and 
post-NOX treatment pairs. P values =0.005 compared to PAH+NOX, thus illustrating the significant 
effect of N0X2 inhibitor gp91 in counteracting the COL1A1 Promoter Activity stimulated by SSc-
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4.6 Effect of ERK inhibitor PD98059 on Intracellular ROS  
The MAPK/ERK pathway is one of the predominant signaling pathways 
involved in the regulation and synthesis of Collagen. Extracellular signal-
regulated kinase (ERK) is a member of the mitogen-activated protein kinase 
family is shown to be involved in SMC proliferation and also in both 
vasoconstriction and vascular smooth muscle cell growth [118]. There are 
evidences suggesting that ERK activation occurs via ROS [180,181].With these 
evidences, it was thought that targeting ERK would provide some clues about 
the pro-fibrotic effects of SSc-PAH sera. In this mode of experiment, 15uM ERK 
Inhibitor PD98059 of was pre-loaded to HPASMCs for 1hr before stimulation 
with sera. In the next step, SSc-PAH sera and No-PAH sera in {5% (V/V)} were 
exposed to these cells and intracellular ROS was measured as described in the 
method section. The outcome of this experiment showed ERK Inhibitor 
PD98059 did not effectively inhibit the intracellular ROS in SSc-PAH exposed 
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Figure 5: Effect of ERK inhibitor PD98059 on Intracellular ROS in sera stimulated HPASMCs.Here, 
sub-confluent HPASMCs were incubated for 1 hour with 15 μM ERK inhibitor PD98059 before 
treatment with SSc  sera and measurement of Intracellular ROS in PASMCs exposed to Sera of SSc-
PAH and SSc-No PAH was carried out. Fluorescence data were normalized for protein content and 
expressed as Relative Fluorescence Units (RFU).Wilcoxon matched-pairs signed rank test was used 
to draw differences between pre- and post ERK inhibitor PD98059 treatment pairs. P values  › 0.05 
when compared to PAH+PD as well as No PAH+ PD thus illustrating the non-significant effect of 
ERK inhibitor PD98059 in counteracting the intracellular ROS stimulated by SSc-PAH and SSc-No 
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4.7 Effect of ERK inhibitor PD98059 on Collagen type I (COL1A1) 
promoter Activity  
In this experiment, lentivirus transduction in HPASMCs was done. This is 
followed by the confirmation of the transduction of lentiviral particles in the 
cells by using fluorescence microscope by observing the Green fluorescence 
provided by the GFP reporter system. The next step was done by pre-
incubating the transduced cells by 15uM ERK Inhibitor PD98059 for 1hr.Then 
HPASMCs were exposed with 5% (V/V) sera of SSc-PAH and No-PAH. This 
step was followed by the measurement of COL1A1 promoter activity. The 
outcome of this experiment was that ERK Inhibitor PD98059 efficiently 
reduced (Fig.6) the COL1A1 promoter activity in SSc-PAH sera exposed 
HPASMCs, but the similar effect was not observed in No-PAH sera exposed 
HPASMCs, as the inhibitor did not significantly reduced  COL1A1 promoter 
activity. So the result from this experiment proved that ERK signaling is 
involved in the activation of COL1A1 promoter activity in the HPASMCs 
exposed only with sera of SSc-PAH, but not the similar effect was observed in 
case of No-PAH, confirming that sera of SSc-PAH had pro-fibrotic effect on 
HPASMcs  thereby suggesting that    phenotypic switch and collagen synthesis 
activation in HPASMCs may be driven by SSc-related PAH sera through ERK 
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Figure 6: Effect of ERK inhibitor PD98059 on COL1A1 Promoter Activity in sera stimulated 
HPASMCs. Here, sub-confluent HPASMCs were transduced with lentiviral particles obtained from 
the COL1A1-LV-tGFP and EF1α-LV-FP602 lentivectors, and then incubated for 1 hour with15 μM 
ERK inhibitor PD98059 before treatment with 5% (V/V) of sera from PAH, no PAH and COL1A1 
Promoter Activity was measured . Data are normalized for transduction efficiency by reporting the 
ratio of COL1A1-LV-tGFP to EF1α-LV-FP602 Relative Fluorescence Units (RFU). Wilcoxon matched-
pairs signed rank test was used to draw differences between pre- and post ERK inhibitor PD98059 
treatment pairs. P values =0.039 when compared to PAH+PD thus illustrating the significant effect 
of ERK inhibitor PD98059 in counteracting the COL1A1 Promoter Activity stimulated by SSc-PAH 
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CHAPTER 5. DISCUSSION AND CONCLUSION 
 
Most patients in SSc die due to pulmonary involvement of the disease with SSc 
PAH in second place to ILD PH. But SSc-PAH has worse prognosis than that of 
IPAH [39] and patients are at higher risk of death than IPAH patients or ILD 
PH. PAH is a life-threatening ailment, which could rapidly progress to severe 
right heart failure [13,14] and hence death of the patient occurs in very short 
time. So, it has thus become extreme need to study SSc-PAH, in particular the 
cellular and molecular events of the disease that set the vascular damage by 
OS during its disease pathogenesis, as OS is largely evidenced in this disease. 
In our Study, the first need was the selection of the subjects and so the study 
subjects were selected based on the diagnostic characters that divide SSc-PAH 
from No-PAH in overall SSc patients that came under this study and they were 
mostly middle age, white women. A total number of 19 SSc patients were 
diagnosed as SSc-PAH and 17 patients were selected as SSc No-PAH based on 
the diagnostic criteria. SSc-PAH is more common in LcSSc, when compared to 
DcSSc, however few recent studies [30-38] suggest that the prevalence of PAH 
is similar in both limited and diffuse cutaneous SSc patients. But in our study 
cases, PAH has shown higher in LcSSc with 16 patients showed PAH in total of 
84 LcSSc patients against only 3patients showed PAH in total of 16 DcSSc 
patients as depicted in the Table A. It has been proved by many reports that 
PAH occurs as a late age onset[152-156] in SSc and so in our study case also 
the trend remains exactly the same with PAH prevailing at age of 64.0 ± 9.4 vs 
53.3 ± 11.6 along with healthy donors age of 54.1 ± 10.4; p= 0.009. And  in our 
study cohort, it is also noticed that the prevalence of PAH being present in the 
SSc patients having the disease for longer durations with a  duration(RP 
onset) of 21.7 ± 9.4, against the non-PAH SSc patients duration of 14.0 ± 12.6 ; 
p= 0.008 matching with many  earlier reports[152-156]. Increased collagen 
leads to skin thickness, which is due to intercellular matrix formation in the 
dermis and by oedema, possibly affected by both microvascular injury and  
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inflammation. Rodnan skin score (mRSS) is the ‘gold standard’ method for                                                                                                              
measuring the skin thickness in scleroderma [182].Few groups have tried to 
link this score to the severity of organ involvements in SSc, but, unfortunately 
this skin score measurement remained only to assess the thickening of skin in 
SSc pateints and could not be evolved as a biomarker to relate to the organ 
based severities such as pulmonary and cardiac involvements [183]. The 
Rodnan skin score (mRSS) in our study remain slight higher in SSc-PAH but 
not to the significant level when compared to No-PAH. However, their study 
[183] showed that mRSS greater than score 3 linked to pulmonary fibrosis but 
similar distribution was present when compared with other patients (PAH and 
cardiac involvement) with a higher mRSS clearly uttering the confirmation 
that Rodnan skin score (mRSS) did not serve as a biomarker in distinguishing 
the organ involvement defects in SSc.RP severity scores and Heart severity 
scores were little bit higher in SSc-PAH vs No-PAH, but not to the significant 
level of difference between the subjects. These scores indicate the level of 
vascular damages that are being fabricated by the disease condition and the 
higher scores in our studies exhibited the severity in pulmonary vascular 
condition that is also reported [184] by other studies. The Lung severity 
scores remained higher in SSc-PAH against non-PAH which are in compliance 
with the data of the other published reports [184-187].These features 
strongly show that there exists pulmonary vascular damage due to the 
prevalence of pulmonary vascular disease. Cardiac hemodynamic 
measurements by Right heart Catheterization showed that mean pulmonary 
arterial pressure (mPAP) and pulmonary capillary wedge pressure (PCWP) 
were remained in the range as expected to be in SSc-PAH subjects. There was 
comparatively lower diffusion capacity of lung for carbon monoxide (DLCO) 
(48.7 ± 16.8 vs 78.2 ± 23.0; p < 0.001) with comparable forced vital capacity 
(FVC) with decreased values against No-PAH subjects, which provided the 
confirmed clues that there exists an underlying pulmonary vascular disease. 
SSc-PAH patients showed significantly higher estimated right ventricular  
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systolic pressure (ERVSP) values (65.2 ± 19.9 vs 24.0 ± 6.3, p= <0.001) when 
compared to those of Non-PAH subjects this observation provided the severity                                                                                                                 
of the underlying pulmonary vascular disease as RVSP >45 mm Hg cutoff has 
demonstrated to have high correlation with PAH detected by RHC [184, 189] 
that provides the proof of severe disturbances in the pulmonary vascular bed.  
Demographic Studies have shown Anti centromere antibodies (ACA) is 
prevalent in older, female Caucasians having SSc [161], so the same case in 
our study as well. The antibody status in our study revealed that SSc-PAH 
subjects showed not though significant but slight higher level of Anti 
centromere antibodies against No-PAH, because prevalence of ACAs linked 
with higher risk of development of PAH [161, 162] in SSc patients particularly 
the lSSc patients [161]. Anti-Scl-70 (anti-topoisomerase I) antibodies in this 
study were found lower in SSc-PAH against the No-PAH subjects very relevant 
to earlier studies [161,163,164] as SSc-PAH subjects mostly from lcSSc 
subjects but not dcSSc having interstitial lung disease showed the similar 
condition. There have been reports saying that there is complex interaction 
between endothelial cells (ECs), smooth muscle cells (SMCs), pericytes, 
extracellular matrix (ECM), and intravascular circulating factors [167]. Serum 
from long been has provided the useful tool in the diagnosis of many diseases. 
So also in our study has provided a very significant knowledge in 
understanding the SSc-PAH, by showing the proof that OS is linked to SSc-
PAH. Serum factors in-vitro induced ROS production in Vascular cells [166]. 
The generation of ROS by vascular cells can activate several processes that 
elicit the development of SSc [190]. These could exhibit the underlying 
disease. So, this background provides us a hint that abnormalities in 
circulatory factors such as sera could be tested in-vitro to study the molecular 
and cellular events of the vascular damage during SSc, particularly in SSc-PAH. 
From our study the concept has been evolved which proves that ROS status 
can be identified as an indicator of the disease which could become a tool in 
the diagnosis and thereby becoming an aid in targeting the disease  
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mechanism and pursuing the remedy in SSc disease including SSc-PAH.In our 
study, when the sera from SSc were tested over the Human pulmonary artery 
Smooth Muscle Cells (HPASMCs), it was noticed that SSc sera induced the ROS 
production. When the Kinetic  measurement of intracellular ROS was done in 
PASMCs by exposing to the SSc sera, the result showed that SSc-PAH sera 
induce more level of ROS significantly compared to the SSc with “No PAH” as 
well against the sera of Healthy Donors(HD).This proves that circulatory 
factors  execute the pro-oxidant effect on HPASMCs. Endogenous pro-oxidants 
may be formed as the derivatives of the abnormal pathophysiology, cellular 
metabolism and ion flux [56], such kind of unusual or abnormalities are 
evolved due to the underlying disease, and this concept has been greatly 
evolved in our study which showed that pro-oxidants may be present in the 
sera of SSc-PAH patients which stimulated intracellular ROS and COL1A1 
promoter activity in HPASMCs by inducing HPASMCs activation and 
phenotypic switch and  if this process is not regulated would  lead to the 
progressive narrowing and obliteration of pulmonary arterioles in SSc-
PAH.This implies that circulating pro-oxidant factors may be involved in the 
pathogenesis of SSc-PAH through their ability to induce VSMCs activation and 
phenotypic switch.NADPH oxidases are widely distributed throughout 
different tissues and organs with only sole function to produce ROS. From our  
study it was revealed that NOX2 inhibitor gp91 very significantly reduced the 
intracellular ROS produced by the exposure of SSc-PAH sera, strongly 
implicating that cell membrane intracellular ROS are involved in the induction 
of Oxidative stress in SSc-PAH  and more specifically indicating that NOX2 is 
involved in the process. But the same scenario was not observed in case of No-
PAH subjects, evidencing, that oxidative stress is very prominently implicated 
in the pathogenesis and development of hypertension arterial disease of SSc 
condition.This observation also provided the proof that redox status is not 
balanced in SSc-PAH subjects which has led to the development OS in SSc-
PAH. There are reports evidencing the same picture as in our study stating  
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that ROS are formed in high concentrations, in pathological conditions, such as 
hypertension, that cannot be balanced by the normal protective antioxidant 
mechanisms employed by the cells, resulting in oxidative stress [64, 109-
111,113, 115,191-193]. The result that has been procured from our studies   
also showed more intracellular ROS as compared to the No-PAH SSc patients 
clearly indicating the higher level of intracellular ROS in this disease 
phenomena. Besides, the result from the kinetic measurement of intracellular 
ROS showed that, from the start of the measurement till the end the level, ROS 
was relatively higher than that of the No-PAH SSc subjects which strongly 
supports the earlier reports that SSc-PAH disease condition physiology is 
involved with the production of intracellular ROS. This condition would lead 
to many abnormalities in the vascular wall as follows. This could cause the 
subsequent pathogenic process in the vascular wall posing inflammation and 
deteriorations in the functions of endothelium in vasodilation, with increased 
pro-inflammatory states and increased prothrombotic activity. This would 
further cause vascular inflammation and OS may mediate through activation 
of mononuclear cells [58, 59] with infiltration of inflammatory cells in 
pulmonary perivascular spaces within and around plexiform lesions [60–62]. 
This further would stimulate a variety of negative effects on cellular function 
involving alteration of transcription factors, kinases, protein synthesis and 
also would cause   increase in vascular contractility, also  would  promote 
vascular smooth muscle cell growth and apoptosis, monocyte migration, lipid 
peroxidation, inflammation, and increased deposition of ECM proteins. These 
all events play a pivotal role in the pathogenesis and progression of vascular 
damage, vascular remodeling in vascular diseases [65-67] including SSc-PAH. 
The major pathophysiologic event that occurs in the development of 
pulmonary hypertension is the proliferation of vascular smooth muscle cells 
and it has been shown that extracellular signal-regulated kinase (ERK) is a 
member of the mitogen-activated protein kinase family that has been 
reported to be involved in both vasoconstriction and vascular smooth muscle  
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cell growth [118] which prompted us to relate, whether the ROS generation 
and collagen promoter activity is dependent on ERK activation. That’s why we 
employed ERK Inhibitor PD98059 in our study to look for ERK involvement. 
HPASMCs were pre-incubated with ERK Inhibitor PD98059 and then were 
exposed to sera (SSc-PAH & SSc-No-PAH). In this experiment, the ERK 
Inhibitor PD98059 could not form significant effect in reducing the 
intracellular ROS (Fig 5) in HPASMCs exposed to both the subjects of sera, 
confirming that, ERK was not involved in the generation of intracellular ROS. 
In another experiment, we planned to look for involvement of ERK in collagen 
promoter activity. The outcome of this experiment showed that ERK Inhibitor 
PD98059, very effectively (p=0.039)counteracted the COL1A1 promoter 
activity(Fig 6) in HPASMCs that were exposed to SSc-PAH sera, but the same 
effect was not reproduced in case of No-PAH  SSc sera exposed HPASMCs. This 
result indeed confirmed that ERK was involved in the activation of COL1A1 
promoter activity and hence in the synthesis of collagen in the HPASMCs that 
were exposed to SSc-PAH sera. This in-vitro study implies that in the patients 
of SSc-PAH, the ERK pathway is involved in the activation and synthesis of 
collagen I and hence in the accumulation of ECM in the vascular wall causing 
vascular remodeling and  progressive vessel occlusion and thus involving or 
leading to pulmonary arterial hypertension. By looking into the complete 
account of the outcomes of our study, it can be summarized that SSc-PAH sera 
induced pro-oxidant effect on HPASMCs and hence there occurred the 
generation of intracellular ROS, which suggests that pro-oxidant effect 
existence in the sera may be due to the endogenous pathophysiology of the 
disease condition. This further suggests that the pathophysiology of the 
disease involves Oxidative Stress (OS), which may be due to the vascular 
damage derived from the abnormal changes in cellular and molecular status of 
the disease condition thereby, exhibiting the notion that OS is linked to SSc-
PAH [66-70,173] and as well as giving a hint that OS can be considered as one 
of the etiological factor in SSc-PAH. Further, when examined for the source of  
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intracellular ROS by using specific inhibitor NOX2ds-tat (NOX), it was found 
that NADPH Oxidases (NOX) are the one participated in the generation of 
intracellular ROS in the vascular bed in compliance with the earlier reports 
[106-108,112,193-208] that have been reported in vascular diseases. The 
evidence from our study implicates for therapeutically targeting NOX2 
oxidase in the arterial wall for the treatment of SSc-PAH, so as to combat the 
oxidative stress and prevent the progression of pulmonary vascular disease 
such as SSc-PAH in agreement with the earlier reports [106, 129, 136,194-
205]. In other experiments, the outcomes were that, ERK Inhibitor PD98059 
did not effectively inhibit the intracellular ROS in SSc-PAH exposed HPASMCs 
but efficiently reduced the COL1A1 promoter activity in SSc-PAH sera exposed 
HPASMCs. Prior, to this it was gathered from our result, that ROS generation 
exists via NADPH Oxidases (NOX2).These findings can be collectively 
explained that sera of SSc-PAH stimulated the activation of NOX2, which 
resulted in the generation of intracellular ROS. The intracellular ROS 
generated by NOX through its activation by the pro-oxidant effect of sera, 
further activated ERK resulting in the activation of COL1A1 promoter activity 
and hence the synthesis of Collagen as illustrated by the figure below. Hence, 
the sera of SSc-PAH, in our study, exhibited the pro-oxidant effect by 
activating NOX enzymes. It is well evidenced in various reports [210-227] that 
NADPH Oxidase is activated by various cellular stresses, chemical factors, and 
physical challenges, cellular environments, and inflammatory stimuli, stress-
related humoral and neural factors. And, in our studies, it is emerging that the 
pro-oxidant effect executed by the SSc-PAH sera may be due to the one of the 
above said factors and it is speculated that circulating pro-oxidant factors may 
be involved in the pathogenesis of SSc-PAH through their ability to induce 
VSMCs activation and phenotypic switch. With these findings our study  
provides new evidence supporting the possibility that, vascular disease and in 
particular PAH may be driven or maintained in SSc patients by pro-oxidant  
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circulating factors acting, at least in part, through the activation of collagen 












Figure 7: Representative Diagram to show that Sera from SSc-PAH subjects stimulate NOX in HPASMCs for ROS 
generation thus exhibiting the Pro-oxidant effect, which subsequently exhibit the Pro-fibrotic effect by 
synthesizing Collagen I via the stimulation of ERK. 
 
To conclude, our study for the first time, shows that an increase of NOX2-
derived ROS production induced by sera from SSc patients with PAH drives 
pro-oxidant and as well as pro-fibrotic responses in HPASMCs by activating 
ERK-mediated collagen synthesis. Hence, our study further suggests that 
antioxidant therapies should be explored in the treatment or prevention of 
Systemic Sclerosis related pulmonary vascular disease.  
Sera of SSc-PAH 
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